These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2242261)

  • 1. The in vivo biologic effect of interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer.
    Schantz SP; Clayman G; Racz T; Grimm EA; Liu FJ; Lavedan P; Taylor D; Pellegrino C; Savage H
    Arch Otolaryngol Head Neck Surg; 1990 Nov; 116(11):1302-8. PubMed ID: 2242261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
    Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
    Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of serum inhibitory factors and immune cellular defects to the depressed cell-mediated immunity in patients with head and neck cancer.
    Wanebo HJ; Blackinton D; Kouttab N; Mehta S
    Am J Surg; 1993 Oct; 166(4):389-94. PubMed ID: 8214299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of lymphokine-activated lymphocytes. Lysis of human head and neck squamous cell carcinoma cell lines.
    Alessi DM; Hutcherson RW; Mickel RA
    Arch Otolaryngol Head Neck Surg; 1989 Jun; 115(6):725-30. PubMed ID: 2785809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma.
    Hersey P; MacDonald M; Hall C; Spurling A; Edwards A; Coates A; McCarthy W
    Cancer; 1986 Apr; 57(8 Suppl):1666-74. PubMed ID: 3485011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
    Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
    Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute-phase proteins in patients with head and neck cancer treated with interleukin 2/interferon alfa.
    Clayman GL; Liu FJ; Savage HE; Taylor DL; Lavedan P; Buchsbaum RM; Pellegrino C; Trujillo JM; Young G; Schantz SP
    Arch Otolaryngol Head Neck Surg; 1992 Jan; 118(1):41-8. PubMed ID: 1370199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.
    Melioli G; Margarino G; Scala M; Mereu P; Bertoglio S; Schenone G; Barbaresi M; Machí AM; Santi L; Badellino F
    Laryngoscope; 1992 May; 102(5):572-8. PubMed ID: 1533435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
    Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
    Fiorentino B; Di Stefano P; Giuliani C; Amatetti C; Tinari N; Natoli C; Garufi C; Iacobelli S
    Br J Cancer; 1992 Nov; 66(5):981-3. PubMed ID: 1419647
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential sensitivity of head and neck cancers to non-major histocompatibility-restricted killer cell activity.
    Schantz SP; Racz T; Ordonez NG; Terry N; Taylor DL; Bugis S; Sacks PG
    J Surg Res; 1990 Feb; 48(2):154-64. PubMed ID: 2106056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peri-operative modulation of cellular immunity in patients with colorectal cancer.
    Nichols PH; Ramsden CW; Ward U; Trejdosiewicz LK; Ambrose NS; Primrose JN
    Clin Exp Immunol; 1993 Oct; 94(1):4-10. PubMed ID: 8403515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells.
    Clayman GL; Taylor DL; Liu FJ; Lavedan P; Savage HE; Schantz SP
    Laryngoscope; 1993 Mar; 103(3):299-307. PubMed ID: 7680086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
    Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies.
    Sosman JA; Hank JA; Sondel PM
    Semin Oncol; 1990 Feb; 17(1 Suppl 1):22-30; discussion 38-41. PubMed ID: 2405492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.
    Foa R; Guarini A; Gillio Tos A; Cardona S; Fierro MT; Meloni G; Tosti S; Mandelli F; Gavosto F
    Cancer Res; 1991 Feb; 51(3):964-8. PubMed ID: 1988139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune restoration with interleukin-2 in patients with squamous cell carcinoma of the head and neck.
    Wanebo HJ; Jones T; Pace R; Cantrell R; Levine P
    Am J Surg; 1989 Oct; 158(4):356-60. PubMed ID: 2802041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.